Your browser doesn't support javascript.
The impact of COVID-19 on pragmatic clinical trials: lessons learned from the NIH Health Care Systems Research Collaboratory.
O'Brien, Emily C; Sugarman, Jeremy; Weinfurt, Kevin P; Larson, Eric B; Heagerty, Patrick J; Hernandez, Adrian F; Curtis, Lesley H.
  • O'Brien EC; Department of Population Health Sciences, School of Medicine, Duke University, 215 Morris Street, Suite 210, Durham, NC, 27701, USA. emily.obrien@duke.edu.
  • Sugarman J; Duke Clinical Research Institute, School of Medicine, Duke University, Durham, NC, USA. emily.obrien@duke.edu.
  • Weinfurt KP; Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD, USA.
  • Larson EB; Department of Population Health Sciences, School of Medicine, Duke University, 215 Morris Street, Suite 210, Durham, NC, 27701, USA.
  • Heagerty PJ; Duke Clinical Research Institute, School of Medicine, Duke University, Durham, NC, USA.
  • Hernandez AF; Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
  • Curtis LH; Department of Biostatistics, University of Washington, Seattle, WA, USA.
Trials ; 23(1): 424, 2022 May 21.
Article in English | MEDLINE | ID: covidwho-1951314
ABSTRACT

BACKGROUND:

The COVID-19 pandemic has considerably disrupted nearly all aspects of daily life, including healthcare delivery and clinical research. Because pragmatic clinical trials are often embedded within healthcare delivery systems, they may be at high risk of disruption due to the dual impacts on the conduct of both care and research.

METHODS:

We collected qualitative data using multiple methods to characterize the impact of COVID-19 on the research activities of 14 active pragmatic clinical trials in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory. A COVID-19 impact questionnaire was administered electronically to principal investigators in June 2020. Text responses were analyzed thematically, and qualitative summaries were subsequently reviewed by five independent reviewers, who made iterative revisions. Additional COVID-19-related impacts were identified during virtual meetings with trial teams during April-July 2020 and combined with questionnaire responses for analysis.

RESULTS:

Impacts of the pandemic were broadly classified into two main types healthcare operations and social distancing. In some instances, trial delays created statistical challenges, particularly with trials using stepped-wedge designs, and necessitated changing data collection strategies or modifying interventions. The majority of projects used existing stakeholder-driven approaches to adapt interventions. Several benefits of these adaptions were identified, including expanded outreach capabilities and ability to study virtual intervention delivery. All trial teams were able to adapt to pandemic-related modifications.

CONCLUSION:

In a group of 14 ongoing pragmatic clinical trials, there was significant impact of COVID-19 on trial activities. Engaging appropriate stakeholders was critical to designing and implementing trial modifications and making continued safe progress toward meeting research objectives.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pragmatic Clinical Trials as Topic / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Trials Journal subject: Medicine / Therapeutics Year: 2022 Document Type: Article Affiliation country: S13063-022-06385-8

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pragmatic Clinical Trials as Topic / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Country/Region as subject: North America Language: English Journal: Trials Journal subject: Medicine / Therapeutics Year: 2022 Document Type: Article Affiliation country: S13063-022-06385-8